Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology

Human embryonic stem cell (hESC) progenies hold great promise as surrogates for human primary cells, particularly if the latter are not available as in the case of cardiomyocytes. However, high content experimental platforms are lacking that allow the function of hESC-derived cardiomyocytes to be studied under relatively physiological and standardized conditions. Here we describe a simple and robust protocol for the generation of fibrin-based human engineered heart tissue (hEHT) in a 24-well format using an unselected population of differentiated human embryonic stem cells containing 30–40% α-actinin-positive cardiac myocytes. Human EHTs started to show coherent contractions 5–10 days after casting, reached regular (mean 0.5 Hz) and strong (mean 100 µN) contractions for up to 8 weeks. They displayed a dense network of longitudinally oriented, interconnected and cross-striated cardiomyocytes. Spontaneous hEHT contractions were analyzed by automated video-optical recording and showed chronotropic responses to calcium and the β-adrenergic agonist isoprenaline. The proarrhythmic compounds E-4031, quinidine, procainamide, cisapride, and sertindole exerted robust, concentration-dependent and reversible decreases in relaxation velocity and irregular beating at concentrations that recapitulate findings in hERG channel assays. In conclusion this study establishes hEHT as a simple in vitro model for heart research.

[1]  G. Keller,et al.  Identification and targeting of the ROSA26 locus in human embryonic stem cells , 2007, Nature Biotechnology.

[2]  Lila R Collins,et al.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.

[3]  Thomas Rau,et al.  Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Yunqing Shi,et al.  Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. , 2003, Developmental cell.

[5]  K. Bendixen,et al.  Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue , 2009, Proceedings of the National Academy of Sciences.

[6]  Thomas Eschenhagen,et al.  Three‐dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  C. Mummery,et al.  Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. , 2008, Differentiation; research in biological diversity.

[8]  Rene Spijker,et al.  Differentiation of Human Embryonic Stem Cells to Cardiomyocytes: Role of Coculture With Visceral Endoderm-Like Cells , 2003, Circulation.

[9]  Lieven Thorrez,et al.  Drug‐screening platform based on the contractility of tissue‐engineered muscle , 2008, Muscle & nerve.

[10]  Wolfram-Hubertus Zimmermann,et al.  Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue. , 2007, Journal of molecular and cellular cardiology.

[11]  A. Everett.  Isomyosin expression in human heart in early pre- and post-natal life. , 1986, Journal of molecular and cellular cardiology.

[12]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[13]  Chunhui Xu,et al.  Feeder-free growth of undifferentiated human embryonic stem cells , 2001, Nature Biotechnology.

[14]  Robert Passier,et al.  Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[15]  M. Hashimoto,et al.  [Draft ICH guideline S7B: guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals]. , 2003, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[16]  Wei-Zhong Zhu,et al.  Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells , 2010, Circulation research.

[17]  Xuan Yuan,et al.  A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability , 2011, PloS one.

[18]  W. Zimmermann,et al.  Tissue Engineering of a Differentiated Cardiac Muscle Construct , 2002, Circulation research.

[19]  L Gepstein,et al.  Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. , 2001, The Journal of clinical investigation.

[20]  Thomas Rau,et al.  Atorvastatin desensitizes β‐adrenergic signaling in cardiac myocytes via reduced isoprenylation of G‐protein γ‐subunits , 2006 .

[21]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[22]  Shulamit Levenberg,et al.  Tissue Engineering of Vascularized Cardiac Muscle From Human Embryonic Stem Cells , 2007, Circulation research.

[23]  Andreas Hess,et al.  Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts , 2006, Nature Medicine.

[24]  G. Daley,et al.  Human embryonic stem cells , 2004, Bone Marrow Transplantation.

[25]  Lior Gepstein,et al.  A photopolymerizable hydrogel for 3-D culture of human embryonic stem cell-derived cardiomyocytes and rat neonatal cardiac cells. , 2009, Journal of molecular and cellular cardiology.

[26]  M. Bönstrup,et al.  Development of a Drug Screening Platform Based on Engineered Heart Tissue , 2010, Circulation research.

[27]  Eric D. Adler,et al.  Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.

[28]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[29]  Charles E. Murry,et al.  Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture , 2011, Circulation research.

[30]  Jürgen Hescheler,et al.  Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types , 1993, Mechanisms of Development.